Hepatocellular Carcinoma study: ZW251
Official title A Study of ZW251 in Participants With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT07164313
What this study is testing
What is ZW251?
ZW251 is an investigational antibody-drug conjugate being studied for advanced cancers such as hepatocellular carcinoma. ZW251 is designed to target the glypican-3 protein on cancer cells and deliver a toxic payload to kill those cells.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if ZW251 is safe and can help treat advanced cancers such as liver cancer, lung cancer, or germ cell tumors.
- Who it's for
- It is looking for adults who have advanced hepatocellular carcinoma, squamous cell non‑small cell lung cancer, or germ cell tumors.
- What's involved
- Participants will receive ZW251 and may have blood tests, scans, and other routine safety checks during the study.
- Time commitment
- The study lasts several months and involves regular clinic visits for treatment and monitoring.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or...
- Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and/or metastatic disease
- Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and/or choriocarcinoma predominant component and locally...
- Measurable disease per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
You likely can't join if
- Known additional malignancy that is progressing or that has required active treatment within the last year
- History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy
- Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment
- Known gastrointestinal bleeding within 3 months
- Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease
See the full eligibility criteria
- Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or metastatic disease. Noninvasive methods may be used to confirm diagnosis
- Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and/or metastatic disease
- Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and/or choriocarcinoma predominant component and locally advanced (unresectable) and/or metastatic disease
- Measurable disease per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Liver function status of Child-Pugh Class A (for HCC only)
- Adequate organ function
- Known additional malignancy that is progressing or that has required active treatment within the last year
- History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy
- Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment
- Known gastrointestinal bleeding within 3 months
- Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease
The study team makes the final eligibility decision.
Where it is enrolling
- San Francisco, California, United States
- Santa Monica, California, United States
- Louisville, Kentucky, United States
- Grand Rapids, Michigan, United States
- Hackensack, New Jersey, United States
- New York, New York, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Dublin, Ireland
- Kashiwa, Japan
- Kyoto, Japan
- Osaka, Japan
- Tokyo, Japan
- Lisbon, Portugal
- Vila Nova de Gaia, Portugal
- Barcelona, Spain
- Logroño, Spain
- Madrid, Spain
- Málaga, Spain
- Pamplona, Spain
+ 1 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Francisco, California, United States; Santa Monica, California, United States; Louisville, Kentucky, United States; Grand Rapids, Michigan, United States; Hackensack, New Jersey, United States; New York, New York, United States and 15 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.